Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01632696 · ClinicalTrials.gov registry record · Early Phase 1
Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors
A Early Phase 1 study, sponsored by Peregrine Pharmaceuticals.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 11
- Enrollment target
NCT01632696 is a Early Phase 1 study that was terminated before completion, run by Peregrine Pharmaceuticals. The registered enrollment target is 11 participants.
The verdict
NCT01632696, a Early Phase 1 study, was terminated before completion, sponsored by Peregrine Pharmaceuticals.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
Tumor Imaging of I-124 PGN65 in Solid Tumors
Interventions
- DRUG I-124 PGN650 for PET/CT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2012-06 |
| Est. Completion | 2016-05 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01632696
The ClinicalTrials.gov registry entry for NCT01632696 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Peregrine Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which I-124 PGN650 for PET/CT is the first listed.
NCT01632696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01632696 about?
NCT01632696 is a clinical study titled "Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors". Tumor Imaging of I-124 PGN65 in Solid Tumors
What is the current status of trial NCT01632696?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 11 participants. The study started on 2012-06. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01632696?
The interventions under investigation include: I-124 PGN650 for PET/CT (DRUG).
Who is sponsoring clinical trial NCT01632696?
This trial is sponsored by Peregrine Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.